​

Protara Therapeutics (TARA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

TARA Stock Forecast

Protara Therapeutics (TARA) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 128.14% increase from the last price of $5.26.

- $3 $6 $9 $12 $15 High: $12 Avg: $12 Low: $12 Last Closed Price: $5.26

TARA Stock Rating

Protara Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

TARA Price Target Upside V Benchmarks

TypeNameUpside
StockProtara Therapeutics128.14%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$12.00
Last Closing Price$5.26$5.26$5.26
Upside/Downside--128.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2616---7
Feb, 2616---7
Jan, 26-6---6
Dec, 25-6---6
Nov, 2515---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 16, 2025George FarmerScotiabank$12.00$4.00200.00%128.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2026Cowen & Co.BuyBuyhold
Jan 07, 2026Piper SandlerOverweightinitialise
Apr 16, 2025ScotiabankOutperforminitialise
Dec 05, 2024Cowen & Co.BuyBuyhold
Aug 06, 2024Cowen & Co.BuyBuyhold
Apr 05, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.57$-2.17$-1.34---
Avg Forecast$-3.57$-3.32$-3.40$-2.18$-2.33$-1.34
High Forecast$-3.17$-2.23$-1.79$-1.42$-1.69$-1.34
Low Forecast$-3.84$-5.93$-6.90$-2.93$-2.96$-1.34
Surprise %--34.64%-60.59%---

Revenue Forecast

$0 $14M $28M $42M $56M $70M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$3.22M$24.87M$22.30M$6.35M$66.50M
High Forecast-$3.22M$24.87M$22.30M$6.35M$66.50M
Low Forecast-$3.22M$24.87M$22.30M$6.35M$66.50M
Surprise %------

Net Income Forecast

$-80M $-67M $-54M $-41M $-28M $-15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-40.42M$-44.60M$-57.44M---
Avg Forecast$-40.42M$-42.05M$-55.06M$-24.65M$-26.35M$-15.18M
High Forecast$-35.90M$-25.26M$-20.23M$-16.09M$-19.15M$-15.18M
Low Forecast$-43.56M$-67.25M$-78.16M$-33.20M$-33.54M$-15.18M
Surprise %-6.06%4.33%---

TARA Forecast FAQ

Is Protara Therapeutics stock a buy?

Protara Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Protara Therapeutics is a favorable investment for most analysts.

What is Protara Therapeutics's price target?

Protara Therapeutics's price target, set by 5 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 128.14% change from the previous closing price of $5.26.

How does Protara Therapeutics stock forecast compare to its benchmarks?

Protara Therapeutics's stock forecast shows a 128.14% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Protara Therapeutics over the past three months?

  • March 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Protara Therapeutics’s EPS forecast?

Protara Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.18, marking a 62.69% increase from the reported $-1.34 in 2025. Estimates for the following years are $-2.33 in 2027, and $-1.34 in 2028.

What is Protara Therapeutics’s revenue forecast?

Protara Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $22.3M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $6.35M, and $66.5M for 2028.

What is Protara Therapeutics’s net income forecast?

Protara Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-24.646M, representing a -57.09% decrease from the reported $-57.439M in 2025. Projections indicate $-26.345M in 2027, and $-15.184M in 2028.